TABLE 3.

Incidence of adverse events

Adverse eventa	No. (%) of adverse events for group
	Telbivudine (n = 23)	Entecavir (n = 21)
ALT level increased	3 (13.0)	1 (4.8)
Upper respiratory tract infection	1 (4.3)	2 (9.5)
Chest discomfort	1 (4.3)	1 (4.8)
Abdominal discomfort	1 (4.3)	0 (0.0)
Abdominal pain, upper	1 (4.3)	0 (0.0)
AST level increased	1 (4.3)	0 (0.0)
Conjunctival hyperemia	1 (4.3)	0 (0.0)
Dyspnea	1 (4.3)	0 (0.0)
Gingival bleeding	1 (4.3)	0 (0.0)
Hypophosphatemia	1 (4.3)	0 (0.0)
Myalgia	1 (4.3)	0 (0.0)
Neutropenia	1 (4.3)	0 (0.0)
Thrombocytopenia	1 (4.3)	0 (0.0)
Blood CK level increased	0 (0.0)	3 (14.3)
Nausea	0 (0.0)	2 (9.5)
Facial edema	0 (0.0)	1 (4.8)
Headache	0 (0.0)	1 (4.8)
Hordeolum	0 (0.0)	1 (4.8)
Insomnia	0 (0.0)	1 (4.8)
Myringitis	0 (0.0)	1 (4.8)
Nasopharyngitis	0 (0.0)	1 (4.8)
Proteinuria	0 (0.0)	1 (4.8)
Vaginal hemorrhage	0 (0.0)	1 (4.8)
Vomiting	0 (0.0)	1 (4.8)
Total	9 (39.1)	13 (61.9)

^aAbbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; CK, creatine kinase.